Watch our video to learn more about our mission and story.
Our journey began in 2010, when the earliest team members began to explore the idea of a diagnostic test that could be used by anyone, anywhere.
While completing an Entrepreneur-in-Residence at Artiman Ventures, Visby founder Adam de la Zerda explores the concept of a diagnostic so simple it could be used by anyone, anywhere.
After researching the market and finding nothing significant, Adam incorporates Click Diagnostics in December. Soon after, Greg Loney joins as a founding executive and the VP of engineering.
Focusing on sexual health
Click Diagnostics explores a number of markets and identifies sexual health as the direction to pursue. Work begins on an STI test focused on women’s health.
First functional prototype
Click Diagnostics develops its first fully integrated device. Small enough to fit in the palm of your hand, the PCR test delivers rapid and accurate results.
FDA clinical study
NIH sponsors the FDA clinical study for the sexual health product.
Sexual Health Test - FDA submission
Click Diagnostics submits its package to the FDA for its sexual health test. By mid-March, the team decides to join the fight against a new SARS pathogen, COVID-19.
In March, Click Diagnostics officially becomes Visby Medical.
Visby Medical COVID-19 Test
By July, Visby Medical has a functional COVID-19 test. It receives its first authorization from the FDA in September.
Visby Medical Sexual Health Test
The Visby Medical Sexual Health Click Test receives FDA clearance and CLIA waiver, making it the first instrument-free PCR test for the detection of Chlamydia, Gonorrhea, and Trichomonas.